6-deoxy-α-D-mannopyranose | 28161-49-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-deoxy-α-D-mannopyranose
• 英文别名: α-D-rhamnose；D-rhamnose；α-D-rhamnopyranose；α-D-Rhap；D-6-deoxy-mannose；α-D-6-deoxy-mannopyranose；alpha-D-rhamnopyranose；(2S,3S,4S,5S,6R)-6-methyloxane-2,3,4,5-tetrol
• CAS: 28161-49-1
• 化学式: C₆H₁₂O₅
• 分子量: 164.158
• InChiKey: SHZGCJCMOBCMKK-PQMKYFCFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  90.2
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  甲基-D-丙噻 在 吡啶 、 sodium tetrahydroborate 、 Amberlite IR-200 (H⁺ form) 、 水 作用下， 以 水 、 二甲基亚砜 、 丙酮 为溶剂， 反应 76.0h， 生成 6-deoxy-α-D-mannopyranose
  参考文献：
  名称：

  Triterpenoid saponins from Becium grandiflorum var. obovatum

  摘要：

  Two new triterpenoid saponins, beciumecine I and 2, were-isolated from the root bark of Becium grandiflorum var, obovatum and their structures established as 3-O-(beta-D-glucopyranosyl) terminolic acid 28-O-beta-D-apiofuranosyl( 1-3)-[alpha-L-rhamnopyranosyl( 1-3)-beta-D-xylopyranosyl( 1-4)]-alpha-L-rhamnopyranosyl(1-2)-alpha-L-arabinopyranoside and 3-O-(beta-D-glucopyranosyl) 24-hydroxyterminolic acid 28-O-alpha-L-rhamnopyranosyl(1-3)-beta-D-xylopyranosyl(1-4)-alpha-L-rhamnopyranosyl(1-2)-alpha-L-arabinopyranoside, respectively. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0031-9422(98)00413-0

文献信息

• Medicament containing a sulfopyranosylacylglycerol derivative
  申请人：TOYO SUISAN KAISHA, LTD.

  公开号：US20020028776A1

  公开（公告）日：2002-03-07

  A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): 1 wherein R 101 represents an acyl residue of an unsaturated higher fatty acid, and R 102 represents a hydrogen atom or an acyl residue of an unsaturated higher fatty acid, and pharmaceutically acceptable salts thereof, as an active ingredient.

  包含至少一种从以下组中选择的化合物的药物：由通用公式(1)表示的化合物组1其中，R101代表不饱和高级脂肪酸的酰基残基，R102代表氢原子或不饱和高级脂肪酸的酰基残基，以及药用可接受的盐作为有效成分。
• ANTI-DANDRUFF SUGARS
  申请人：L'OREAL

  公开号：US20150250698A1

  公开（公告）日：2015-09-10

  The invention relates to the cosmetic use of at least one compounds according to the following formula (I), as an anti-dandruff agent or for preventing and/or treating scalp dandruff: where “sugar” denotes a monosaccharide residue chosen from rhamnose, xylose, fucose, mannose, lyxose, and arabinose; where R, substituting the anomeric oxygen in the sugar (represented by “O” in formula (I)), denotes a radical comprising 6 to 38 carbon atoms chosen from: —a linear or branched, saturated alkyl radical; —a linear or branched, alkenyl radical; said linear or branched saturated alkyl radical being optionally substituted by at least one OH and/or NH2 function; —if “sugar” denotes a mannose residue, R denotes a linear C6-C38 alkyl radical, substituted by at least one OH function or an NH2 function; and the salts and solvates and/or optical isomers thereof, alone or in a mixture, particularly racemic forms. The invention also relates to compounds according to formula (I), and cosmetic compositions containing same.

  本发明涉及至少一种根据以下公式（I）的化合物的化妆品用途，作为抗屑剂或用于预防/治疗头皮屑：其中“糖”表示一个单糖残基，选自鼠李糖、木糖、岩藻糖、甘露糖、来苏糖和阿拉伯糖；其中R代表糖（由公式（I）中的“O”表示）的异构氧上的一个基团，该基团包含6至38个碳原子，选自以下几种：—线性或支链的饱和烷基；—线性或支链的烯丙基；所述的线性或支链的饱和烷基可选择性地被至少一个OH和/或NH2功能基团取代；—如果“糖”表示一个甘露糖残基，R表示一个线性的C6-C38烷基，被至少一个OH功能或NH2功能取代；以及所述化合物的盐、溶剂化物和/或光学异构体，单独或混合使用，尤其是外消旋形式。本发明还涉及根据公式（I）的化合物，以及含有该化合物的化妆品组合物。
• [EN] DI- AND TRI-CATIONIC GLYCOSYLATED ANTITUMOR ETHER LIPIDS, L-GUCOSYLATED GAELS AND RHAMNOSE-LINKED GAELS AS CYTOTOXIC AGENTS AGAINST EPITHELIAL CANCER CELLS AND CANCER STEM CELLS<br/>[FR] ETHERS LIPIDIQUES ANTITUMORAUX GLYCOSYLÉS DI- ET TRICATIONIQUES, GAEL L-GLYCOSYLÉS ET GAEL LIÉS À DU RHAMNOSE UTILISABLES EN TANT QU'AGENTS CYTOTOXIQUES DIRIGÉS CONTRE DES CELLULES ÉPITHÉLIALES CANCÉREUSES ET DES CELLULES SOUCHES CANCÉREUSES
  申请人：UNIV MANITOBA

  公开号：WO2015179983A1

  公开（公告）日：2015-12-03

  Glycosylated Antitumor Ether Lipids (GAELs) kill cancer cells by a nonapoptotic pathway which is an attractive strategy to avoid resistance. To further optimize the antitumor effect, we prepared various analogs of di-, and tri-cationic GAEL analogs differing in the nature of the sugar (D-giucose or L-glucose), the anomeric linkage as well as position of the glycerolipid moiety. The di- and tri-cationic GAELs were synthesized and their in vitro anticancer properties were evaluated against drug resistant and aggressively growing cancer cell lines derived from human breast, prostate, pancreatic and ovarian cancers. The most potent dicationic GAEL analogs were also studied against cancer stem cells obtained from breast BT 474, prostate DU145 and ovarian A2780cp cell lines. Our results indicate that the number of positive charges, the position of the amino substituents and the nature of the sugar have significant effects on the anticancer activities of these compounds. The most active analog kill 50% of the cells at concentration range of 0.5-5μΜ and 90% of the cells at the concentration of 1-10μΜ depending on type of cancer cells.

  糖基化抗肿瘤醚脂质（GAELs）通过一种非凋亡途径杀灭癌细胞，这是一种吸引人的策略，可以避免抗药性。为了进一步优化抗肿瘤效果，我们制备了不同的双-和三-阳离子GAEL类似物，其糖的性质（D-葡萄糖或L-葡萄糖）、缩醛键以及甘油脂类团的位置不同。合成了双-和三-阳离子GAEL类似物，并评估了它们对人类乳腺、前列腺、胰腺和卵巢癌衍生的耐药和快速生长的癌细胞系的体外抗癌性能。最有效的双阳离子GAEL类似物也针对从乳腺BT 474、前列腺DU145和卵巢A2780cp细胞系中获得的癌干细胞进行了研究。我们的结果表明，阳离子数量、氨基取代物的位置和糖的性质对这些化合物的抗癌活性有显著影响。最活跃的类似物在浓度范围为0.5-5μΜ时杀死50%的细胞，在浓度为1-10μΜ时杀死90%的细胞，具体取决于癌细胞类型。
• Two anthraquinone glycosides from Cassia marginata roots
  作者：Janhavi Singh、J. Singh

  DOI：10.1016/s0031-9422(00)81443-0

  日期：1987.1.28

  Abstract From the roots of Cassia marginata, 1,3-dihydroxy-6,8-dimethoxy-2-methyl anthraquinone 3-O-rhamnosyl-(1 → 6)-glucopyranoside and 1,3,5,8-tetrahydroxy-2-methyl anthraquinone 3-O-glucoside have been isolated and their structures elucidated.

  摘要 来自决明子的根，1,3-二羟基-6,8-二甲氧基-2-甲基蒽醌3-O-鼠李糖基-(1 → 6)-吡喃葡萄糖苷和1,3,5,8-四羟基-2-已分离出甲基蒽醌 3-O-葡萄糖苷并阐明了它们的结构。
• Lectin-directed prodrug delivery system
  申请人：Davis Guy Benjamin

  公开号：US20070253942A1

  公开（公告）日：2007-11-01

  The invention provides a kit for lectin-directed prodrug delivery comprising a prodrug and a lectin-directed glycoconjugate, wherein the glycoconjugate is adapted to cleave the prodrug and thereby release the drug. The glycoconjugate generally comprises an enzyme conjugated to a carbohydrate moiety which binds to a lectin. The invention also provides novel glycoconjugates and novel methods of synthesizing prodrugs.

  本发明提供了一种用于凝集素定向前药递送的试剂盒，包括前药和凝集素定向的糖基结合物，其中糖基结合物适应于裂解前药并释放药物。糖基结合物通常包括与结合到凝集素的碳水化合物基团偶联的酶。本发明还提供了新型糖基结合物和新型合成前药的方法。